Palomino Laboratories (PALX) Common Equity (2022 - 2025)

Palomino Laboratories has disclosed Common Equity across 4 years of filings, most recently posting $8.1 million for Q4 2025.

• Common Equity for Q4 2025 came in at $8.1 million, up 44335.15% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.1 million (up 44335.15% YoY), and the FY2025 annual result was $8.1 million, up 44335.15% from the prior year.
• Common Equity came in at $8.1 million for Q4 2025 at Palomino Laboratories, up from $7.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $8.1 million in Q4 2025 to a low of -$991653.0 in Q1 2025.
• The 4-year median for Common Equity is -$18306.0 (2023), against an average of $1.1 million.
• Peak annual rise in Common Equity reached 87763.29% in 2025, while the deepest fall reached 42008.41% in 2025.
• Palomino Laboratories' Common Equity stood at -$27804.0 in 2022, then soared by 34.16% to -$18306.0 in 2023, then changed by 0.0% to -$18306.0 in 2024, then surged by 44335.15% to $8.1 million in 2025.
• The last three Common Equity figures came in at $8.1 million (Q4 2025), $7.3 million (Q3 2025), and -$447236.0 (Q2 2025), per Business Quant data.